Plain-English translation of NCT07233291 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a pilot study testing a medication called roflumilast as a new treatment option for adults with moderate to severe psoriasis. Roflumilast is an oral medication—meaning you take it by mouth—that researchers believe may help reduce psoriasis symptoms and severity. The study will track how well the medication works and monitor for any side effects over a 12-week period.
Current treatments for moderate to severe psoriasis don't work well enough for everyone, and some patients experience side effects or lose effectiveness over time. Researchers want to see if this medication could offer a new, safer, or more effective option for people living with psoriasis.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take the oral medication roflumilast daily for 12 weeks. You'll attend multiple scheduled visits where researchers will examine your skin, check how severe your psoriasis is using a standard measurement tool, perform routine blood tests, and ask about any side effects you may be experiencing. During these visits, you'll also share detailed information about your medical history, current medications, and how the treatment is affecting you.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Egypt